Spyre Therapeutics, Inc.
SYRE
$43.91
$4.0210.07%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 44.64M | 45.25M | 40.15M | 41.62M | 50.48M |
| Gross Profit | -44.64M | -45.25M | -40.15M | -41.62M | -50.48M |
| SG&A Expenses | 12.53M | 11.64M | 11.79M | 11.94M | 10.77M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 57.17M | 56.89M | 51.94M | 53.57M | 61.25M |
| Operating Income | -57.17M | -56.89M | -51.94M | -53.57M | -61.25M |
| Income Before Tax | -62.53M | -11.18M | -36.72M | -44.79M | -56.30M |
| Income Tax Expenses | 0.00 | -- | -- | -15.00K | 1.00K |
| Earnings from Continuing Operations | -62.53M | -11.18M | -36.72M | -44.77M | -56.30M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -62.53M | -11.18M | -36.72M | -44.77M | -56.30M |
| EBIT | -57.17M | -56.89M | -51.94M | -53.57M | -61.25M |
| EBITDA | -- | -- | -- | -- | -61.07M |
| EPS Basic | -0.69 | -0.15 | -0.49 | -0.60 | -0.79 |
| Normalized Basic EPS | -0.52 | -0.12 | -0.48 | -0.46 | -0.64 |
| EPS Diluted | -0.69 | -0.15 | -0.49 | -0.60 | -0.79 |
| Normalized Diluted EPS | -0.52 | -0.12 | -0.48 | -0.46 | -0.64 |
| Average Basic Shares Outstanding | 75.09M | 60.41M | 60.33M | 60.27M | 55.26M |
| Average Diluted Shares Outstanding | 75.09M | 60.41M | 60.33M | 60.27M | 55.26M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |